Compass says depression drug has long-lasting benefits
Compass Pathways' psilocybin depression therapy shows six‑month durability, sparking market optimism.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Compass Pathways reported six‑month results from its second Phase 3 trial of the psilocybin‑based compound COMP006, indicating a rapid and durable effect in treating depression. Coverage highlights the positive data, noting share price gains and the company’s plan to seek a launch in the first half of 2027.
Business Wire, Moomoo, Psychedelic Alpha, Endpoints News and STAT all reported on the trial outcomes and the upcoming year‑end filing. Next steps include the anticipated year‑end regulatory filing and a potential H1 2027 market launch, according to the statements in the reports.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 108d ago.
Quick answers
What trial phase and duration were disclosed?
Compass Pathways released six‑month data from its second Phase 3 trial of the psilocybin drug COMP006.
How did investors respond to the data?
Shares of Compass Pathways rose after the positive late‑stage trial results, as noted by Moomoo.
When does the company aim to launch the treatment?
The firm is targeting a launch in the first half of 2027, per the Psychedelic Alpha report.
Coverage (5)
- Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile Business Wire · 110d ago
- Compass Pathways Shares Gain on Positive Late-Stage Trial Data for Depression Treatment Moomoo · 110d ago
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch Psychedelic Alpha · 110d ago
- Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing Endpoints News · 110d ago
- Compass says depression drug has long-lasting benefits STAT · 110d ago
Topics
Related trends
Psilocybin reshapes brain connections through distinct cellular pathways - News-Medical
Recent scientific studies reveal how psilocybin and LSD alter neural circuits, speed up brain activity, and reorganize the brain's global workspace.
Body clock link? New type of depression could affect millions
Coverage examines a newly identified form of depression potentially linked to the human body clock.
Your Sleep Habits May Point to a Specific Type of Depression, a New Study Finds
Recent scientific research reveals a newly identified type of depression tied directly to sleep habits and specific triggers.
What the world's leading researchers think about saunas : Short Wave
Researchers explore the health impacts of sauna use, from clinical trials on depression to long-term studies on life extension.
Body clock disruptions contribute to one in four cases of depression, suggests large study
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Infant hippocampal and amygdala volume in an observational follow-up from a randomized clinical trial for maternal prenatal depression
Recent studies examine how treating maternal prenatal depression through talk therapy impacts infant brain volume.